Gilead Sciences: New Scripts for Harvoni/Sovaldi Decelerating

RBC’s Michael Yee and John Chung have the latest prescription data for Gilead Sciences’ (GILD) hepatitis C treatments, and are predicting U.S. sale of $11.7 billion for the full-year, just consensus estimates. The prescription data for the week ending June 19, showed a 5% decline in total prescriptions written Harvoni compared to the previous week, [...]